Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...

We talk Ozempic, Wegovy and Mounjaro. A number of studies have shown the amazing weight loss potential of a new group of ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Too many young people are prescribed pills for mental illness. Are we repeating history with GLP-1s?

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...